CytoMed Therapeutics (GDTC) IPO deck
Cytomed is focuses on translating its patented technologies into gamma delta (γδ) T cell- and natural killer (NK) cell-based “off-the-shelf” immunotherapeutics for a wide range of cancers.
![](/content/images/size/w1304/2023/04/formfwp_001-1.jpg)
Cytomed is focuses on translating its patented technologies into gamma delta (γδ) T cell- and natural killer (NK) cell-based “off-the-shelf” immunotherapeutics for a wide range of cancers.